BIOR News and Press, Biora Therapeutics Inc. From 08/10/22

SAN DIEGO, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced topline results from its recently completed study PM-602: A Scintigraphic Study to Evaluate the Localization and Delivery Function...

SAN DIEGO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced that it will report second quarter ended June 30, 2022 financial results on Monday, August 15, 2022 after the close of financial m...

SAN DIEGO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced the acceptance of five abstracts for presentation at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting...

SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced that the company’s management team will be participating in one-on-one meetings at the upcoming BTIG Biotechnology Conferen...

SAN DIEGO, July 14, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today shared two posters that were presented at the Controlled Release Society (CRS) 2022 Annual Meeting, which is being held July 11-15, 2022, in...

SAN DIEGO, July 07, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced topline results from its recently completed study PM-611: Safety and Functionality Assessment of the Drug Delivery System (DDS) Ca...

SAN DIEGO, June 22, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced the acceptance of an abstract presenting data on the autonomous triggering and injection efficiency of its systemic therapeutics d...

SAN DIEGO, May 31, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today shared a presentation delivered during Digestive Disease Week® (DDW), May 21-24, 2022 in San Diego. DDW is the world’s premier me...

Patient Data Suggests Multiple Additional Inflammatory Pathways, Supporting Potential Need for Combination Therapy for Ulcerative Colitis Patient Data Establishes Proof of Concept for Microbiome Sampling Capsule SAN DIEGO, May 25, 2022 (GLOBE NEWSWIRE) -- Biora T...

Biora Therapeutics (NASDAQ:BIOR +4.5%) said on Thursday it had received a new patent related to its Drug Delivery System platform, which is under development. The company said the technology is applicable to any ingestible device, whether the device is for sampling, diagnostics, or ...